Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Hematide Shows Non-Inferiority in 4 PIII Trials Overseas: Takeda, Affymax
July 12, 2010
- Korosho to Cancel 30% of Anti-Flu Vaccines from Novartis
July 12, 2010
- Joint Application Submitted for Acetaminophen Dosage Increase
July 12, 2010
- NDA for Anti-CCR4 Antibody to Be Filed Soon: Prof. Ueda
July 12, 2010
- Takeda Appoints Haruhiko Hirate as Corporate Officer
July 12, 2010
- Feraheme Applied for Iron Deficiency Anemia in Europe: Takeda
July 12, 2010
- Interim Analysis of PMS Data Confirms Favorable Safety Profile for Nexavar
July 12, 2010
- NanoCarrier Obtains Patent Related to Polymeric Micelles in Europe
July 12, 2010
- ZERIA to File NDA for Acotiamide in Japan This Fall
July 12, 2010
- Low-Dose SU Effective for Controlling Blood Glucose: JADEC Study
July 12, 2010
- Banyu, Schering-Plough Reorganize Sales, Marketing Structures
July 12, 2010
- Tasigna Approved in 1st-Line Therapy for Ph+ CML in the US
July 12, 2010
- JUPITER Trial Data on Crestor Biased: Prof. Hamazaki
July 12, 2010
- GSK, MTPC to Terminate Copromotion of Adoair
July 12, 2010
- Sawai Considers Entry into Biosimilars Business
July 12, 2010
- Teijin to Create Its Own Marketing Network in China
July 12, 2010
- RA Patients Highly Satisfied with Biologics Treatment: Pfizer
July 12, 2010
- Pfizer Considers Contract Manufacturing Generics in India
July 12, 2010
- 17 New Drugs Recommended for Approval
July 12, 2010
- Astellas Appoints Naoki Okamura as President of OSI Pharm.
July 12, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…